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Activation of aorta thiophosphorylated heavy meromyosin (HMM[SP]) MgZ+-ATPase activity by aorta actin and the 
fraction of HMM[SP]-substrate intermediate complexes bound to actin were measured simultaneously. At 25°C the Km 
for ATPase activation and the dissociation constant for the binding reaction were similar, irrespective of the presence 
or absence of tropomyosin. Aorta caldesmon (0.1 mol/mol actin) inhibited ATPase activation by 8&9Oq6 but did not 
alter the binding of HMM[SP]-product intermediates to actin. It is concluded that caldesmon inhibits by slowing the 
rate-limiting release of products from the actin-HMM[SP] ADP P, complex. 
Caldesmon; Actomyosin; ATPase; Regulation; (Smooth muscle) 
1. INTRODUCTION 
Muscle contraction is regulated by Ca2+ which 
acts on receptor molecules which are components 
of the contractile apparatus. In all muscles, the 
contractile apparatus is made from interdigitating 
filaments of actin and myosin. Force and move- 
ment are produced from cyclic interaction of these 
two proteins at the expense of ATP hydrolysis. 
Ca2+ acts to control the actin-myosin interaction 
and hence ATP hydrolysis. 
The enzymic mechanism of actin-activated 
ATPase hydrolysis has been determined in many 
muscles [1,2] and the kinetic mechanism by which 
several of the control mechanisms, notably the 
troponin system of striated muscles [3] and the 
myosin phosphorylation system of smooth muscles 
[4], control the actomyosin ATPase has also been 
determined. There would appear to be a common 
mechanism: the actin-activated myosin Mg2+- 
ATPase is switched on and off by a change in the 
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rate of the release of products from an ac- 
tin. myosin. ADP . Pi complex, which is the rale- 
limiting step of the reaction. 
Smooth muscles contain two Ca’+-dependent 
regulatory mechanisms: the myosin phosphoryla- 
tion mechanism and a Ca2+-dependent switch 
located in the actin-containing thin filaments [5]. 
Smooth muscle native thin filaments are 
Ca’+-regulated when tested with unregulated 
myosin [6]. The regulatory factors present in 
smooth muscle thin filaments are a high molecular 
mass inhibitor, caldesmon, and a Ca2+-binding 
protein which modulates caldesmon action in 
response to Ca2+ [7,8]. Our recent work has con- 
firmed the regulatory role of caldesmon in aorta 
thin filaments since anti-caldesmon antibodies 
destroy the Ca2+ sensitivity of native thin filaments 
[9] and pure caldesmon has been shown to be able 
to inhibit isometric muscle contraction [lo]. 
Here, we have investigated the mechanism by 
which caldesmon inhibits smooth muscle acto- 
myosin Mg2+-ATPase. Functionally smooth mus- 
cle caldesmon resembles triated muscle troponin 
I + T [l l] and consequently we were particularly 
interested in determining whether the two systems 
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have similar mechanisms. In recently published 
work it has been shown that caldesmon inhibition 
is associated with a large increase in the affinity of 
myosin . ADP - Pi for actin [ 12,131, an observation 
which is difficult to explain on the basis of the 
known mechanism of actomyosin ATP hydrolysis 
[1,2]. We have taken advantage of the properties 
of vascular smooth muscle caldesmon isolated by 
the technique of Smith et al. [7]. We find that this 
form of caldesmon inhibits ATPase without 
changing the affinity of myosin. ADP *Pi for ac- 
tin. From this work we can conclude that 
caldesmon controls the rate-limiting step (product 
release) of the ATPase only and that the very tight 
binding previously observed is not related to the 
regulation of actomyosin Mg’+-ATPase activity. 
2. MATERIALS AND METHODS 
All proteins were prepared from sheep aorta. Native thin 
filaments were isolated according to Marston and Smith [6]. 
Caldesmon and F-actin were obtained from the thin filaments. 
Thin filaments at 10 mg/ml were treated with 0.8 M KC1 and 
centrifuged. Pure actin sedimented and the supernatant con- 
tained caldesmon and other actin-binding proteins. 
Caldesmon was isolated from the supernatant by two pro- 
cedures: (i) the mixture was taken to pH 3 and sedimented at 
low speed. Caldesmon remained in the supernatant and was 
purified by 35-50% ammonium sulphate precipitation [7]. (ii) 
The caldesmon was concentrated and partly purified from the 
mixture by 35-50% ammonium sulphate precipitation. Final 
purification was on a 1 x 15 cm column of Q Sepharose as 
described in [14]. 
Aorta myosin was prepared as in [15] and thiophos- 
phorylated according to [16]. Heavy meromyosin was prepared 
by chymotryptic digestion [4,15]. 
Measurements of MgATP hydrolysis and binding were made 
in 5 mM KsPipes, 2.5 mM MgC12, 1 mM DTT, 0.3 mg/ml 
serum albumin, 2 ,LJM thiophosphorylated HMM (HMM[SP]) 
and O-150 pM actin; pH 7.1 at 25°C. 200-h1 samples were made 
up for each assay point and were split into 2 equal portions. 
One half was used to measure Mg*+-ATPase. MgATP was add- 
ed to 3 mM and after 10 min, 0.5 ml of 5% trichloroacetic acid 
was added to terminate the reaction. The Pi released was 
assayed as in [19]. Control samples containing actin and 
caldesmon but no HMM[SP] were run at the same time and 
these values were subtracted to obtain the ATPase activity. The 
other half of the sample was used for binding measurements. 
MgATP was added to a final concentration of 3 mM and im- 
mediately centrifuged for 20 min at 150000 x g in a Beckman 
airfuge or for 35 min at 150000 x g in lo-ml tubes in a 
preparative ultracentrifuge. The actin and any HMM bound to 
the actin was pelleted. 40-J aliquots of the supernatant after 
sedimentation were taken and the quantity of HMM present 
was assayed by measuring EDTA ATPase activity according to 
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[4]. A negligible quantity of HMM[SP] sedimented in the 
absence of actin; it was therefore assumed that the fraction of 
HMM sedimented in the presence of actin was equal to the frac- 
tion bound to actin. 
3. RESULTS 
Aorta actin activated the Mg’+-ATPase activity 
of thiophosphorylated aorta HMM. Under our 
low ionic strength conditions at 25°C activation 
always followed simple saturation kinetics (fig. 1) 
with a Vmax in the region of 40 min-’ and a K,,, of 
47 + 27 ,xM actin monomer (n = 5). These values 
are similar to our previous data with gizzard pro- 
teins [l]. 
Caldesmon prepared by the method of Smith 
and Marston [7] was a potent inhibitor of actin ac- 
tivation, despite the absence of tropomyosin, 
which was found to be an essential cofactor at 
higher ionic strengths. This observation is in agree- 
ment with [12,13]. At a constant 20 PM actin we 
observed maximum inhibition levels of at least 80 
and 50% of maximum inhibition was obtained at 
1:40 CD/actin (comparable with [7]). When actin 
activation of HMM[SP] Mg2+-ATPase was 
measured in the presence of a maximally inhibiting 
ratio of caldesmon to actin, inhibition was ob- 
served throughout the actin concentration range 
(fig. 1). 
The binding of HMM[SP] . ADP - Pi to actin was 
measured simultaneously with ATPase activation. 
We found that binding followed a simple binding 
curve which extrapolated to 96 + 12% (n = 10) of 
HMM[SP] bound to actin at infinite actin concen- 
tration. The estimated dissociation constant for 
the binding reaction (&) was similar to the K,,, for 
the ATPase activation (fig.1, table 1). This same 
pattern of results was seen when we substituted 
skeletal muscle for smooth actin and in the 
presence and absence of aorta tropomyosin; 
however, with skeletal HMM & was substantially 
higher than Km, as has been previously observed 
[18,19]. 
When the activation was inhibited by 
caldesmon, the binding was not altered. This result 
was always observed with smooth and skeletal ac- 
tins and smooth and skeletal HMM (fig. 1, table 1). 
Since this result differs from that obtained by 
Lash et al. [12], we considered whether the mode 
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Fig.1. Effect of caldesmon on actin activation of HMM[SP] 
Mg’+-ATPase activity and actin-HMM[SP] binding. 
Conditions: HMM buffer at 25”C, 4sM aorta HMM[SP], 
O-80pM actin, 3 mM MgATP. (0) Activation of ATPase by 
actin; (0) activation of ATPase by actin + caldesmon (0.08 
caldesmon/actin mol/mol); (v) binding of HMM[SP] to actin; 
(A) binding of HMM[SP] to actin + caldesmon. Actin 
activation data were fitted to the Michaelis-Menten equation 
(solid line) K,,, = 35.5 + 7,uM, V,,,,, = 16 rt 4 min-‘. Actin 
activation data plotted as % of V,,,; binding results are plotted 
as % sedimented (equal to % bound). 
Table 1 
Comparison of the binding of HMM[SP] .ADP.Pi to actin 
with the Mg’+-ATPase activity in the presence and absence of 
caldesmon 
K,,,A/ % inhi- &A/ n 
&A bition by K~A+CD 
caldesmon 
Aorta actin 
+ aorta HMM[SP] 1.6 88 0.7 3 
Skeletal actin 
+ aorta HMM[SP] 1.6 93 1.06 1 
Aorta actin 
+ skeletal HMM 0.2 92 1.16 1 
Aorta actin 
+ aorta HMM[SP] 
+ aorta tropomyosin 1 .O 78 1.04 2 
Aorta actin 
+ aorta HMM[SP] 
column-purified 
caldesmon 2.1 97 1.2 2 
K,,, and Kd determined with actin (A) or actin + caldesmon 
(A+CD) by fitting the data (6-12 points) to an equation for 
simple binding. SE is about 20%. Where several experiments 
have been done the mean is given. % inhibition is the mean of 
data points (2-4 pairs per experiment) measured in the range 
20-50 pM actin 
of caldesmon preparation might affect the result. 
We prepared caldesmon by a procedure which 
omitted our usual pH 3 treatment and included an 
additional ion-exchange purification step. This 
caldesmon was usually a less potent inhibitor than 
our usual caldesmon but, again, it did not alter the 
binding of HMM[SP] to actin (table 1). 
4. DISCUSSION 
We have investigated the kinetics of vascular 
smooth muscle HMM[SP] Mg’+-ATPase activa- 
tion by actin by steady-state methods. The general 
finding is that activation follows simple Michaelis- 
Menten kinetics and that the K,,, is approximately 
equal to the dissociation constant of the HMM[SP] 
from the actin (&). 
The enzymic pathway of actomyosin is well 
characterised [ 1,2,18]. MgATP binds to actin- 
myosin rapidly and is hydrolysed whilst bound at 
the myosin active site; the substates myosin* . ATP 
and myosin - ADP - Pi are in rapid equilibrium with 
the corresponding attached complexes ac- 
tin - myosin* - ATP and actin - myosin . ADP - Pi. 
The rate-limiting step of the reaction is a confor- 
mational change in actin. myosin . ADP - Pi leading 
to sequential and rapid release of ADP and Pi. In 
this study we found that vascular smooth muscle 
proteins K, = & for the equilibrium between at- 
tached and detached states. This implies that all 
the steps up to the formation of ac- 
tin. myosin . ADP . Pi are rapid relative to the rate- 
limiting step and the intermediate complexes are at 
equilibrium. A similar analysis has been given for 
the gizzard system [1,4]. In the case of skeletal 
HMM, Kd % K, (table 1) because hydrolysis is 
slow relative to the rate-limiting step [18,19]. 
Caldesmon controls actin activation. The 
material we normally work with inhibits actin ac- 
tivation without altering Kd (fig. 1, table 1). On the 
basis of the above pathway, therefore, caldesmon 
must act only by reducing the rate of the slowest 
step. This is a finding of considerable general in- 
terest since it is known that other regulatory 
mechanisms, skeletal muscle troponin, and myosin 
smooth muscle phosphorylation also control 
ATPase hydrolysis predominantly at this step 
[3,41. 
It has been reported that gizzard caldesmon in- 
duces a 40-fold decrease in Kd in actin + smooth 
149 
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HMM systems [12,131. A large decrease in & can- 
not be reconciled with the enzymic mechanism of 
actin activation of HMM[SP] described above and 
in [1,2,4]. Our experiments with caldesmon 
prepared from aorta by the Smith-Marston 
method clearly show that the low & is not a 
necessity for caldesmon inhibition of actin activa- 
tion. It has been tentatively suggested that the tight 
binding of HMM[SP] to caldesmon-containing ac- 
tin filaments involves a site and a mechanism 
which is separate from the acto-HMM ATPase 
mechanism [8,13,20]. Our results support this 
hypothesis. 
The tight binding of HMM to actin-caldesmon 
seems to be a rather labile property of caldesmon; 
whilst it is frequently reported in gizzard systems it 
is rarely seen in aorta. We usually do not observe 
tight binding (table 1) in reconstituted systems but 
tight binding is regularly observed in aorta native 
thin filaments [8]. Furthermore, tight binding is 
critically dependent on myosin type, being much 
more prominent with smooth muscle HMM than 
smooth Sl or skeletal HMM [13]. 
In contrast caldesmon inhibition is a very stable 
property of caldesmon [7,8], consequently it may 
be dissociated from the tight binding phenomenon. 
This has enabled us to establish that caldesmon 
resembles troponin and myosin phosphorylation in 
its regulatory mechanism: all three systems control 
actin activation of myosin Mg’+-ATPase by 
modulating the rate of product release [2-41. 
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